Trials / Unknown
UnknownNCT06008405
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
Phase Ib Clinical Trial of TQB2928 Injection Combination Therapy in Patients With Hematological Malignancies
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study carried out a phase Ib clinical trial of TQB2928 injection combined therapy in patients with hematological malignancies, to explore the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of TQB2928 injection combined with azacitidine for injection in Acute Myeloid Leukemia (AML)/Myelodysplastic Syndromes (MDS) subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2928 Injection + Azacitidine for injection | TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47. Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression. |
Timeline
- Start date
- 2023-09-01
- Primary completion
- 2025-05-01
- Completion
- 2025-05-01
- First posted
- 2023-08-23
- Last updated
- 2023-09-06
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06008405. Inclusion in this directory is not an endorsement.